Lupin is currently trading at Rs. 1148.50, up by 5.65 points or 0.49% from its previous closing of Rs. 1142.85 on the BSE.
The scrip opened at Rs. 1165.75 and has touched a high and low of Rs. 1174.85 and Rs. 1144.50 respectively. So far 80181 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.
Last one week high and low of the scrip stood at Rs. 1176.00 and Rs. 1133.15 respectively. The current market cap of the company is Rs. 51858.39 crore.
The promoters holding in the company stood at 46.70%, while Institutions and Non-Institutions held 40.66% and 12.63% respectively.
Lupin has received final approval for its Fluocinonide Topical Solution USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. Fluocinonide Topical Solution USP, 0.05% had US sales of $32.4 million, as per IMS MAT March 2017.
Lupin’s Fluocinonide Topical Solution USP, 0.05% is AT rated generic equivalent of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1845.75 |
| Dr. Reddys Lab | 1275.50 |
| Cipla | 1333.75 |
| Zydus Lifesciences | 934.50 |
| Lupin | 2243.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: